The Accuracy of Pediatric Air Test as a Non-invasive Atelectasis Diagnostic Tool

NCT ID: NCT04506203

Last Updated: 2023-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-10

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HYPOTHESIS:

During anesthetic pre-oxygenation with high FiO2, pulmonary atelectasis occur, especially in patients \< 6 years old, where FRC and pulmonary closing volume may overlap. New borns and children \<1 year old are especially vulnerable.

OBJECTIVES:

1. Validate "air test" as a individualized and non-invasive diagnostic method of clinically significant atelectasis in pediatrics.
2. Determine what other factors contribute to atelectasis development in pediatrics

METHODS:

30 pediatric patients will be studied with ages ranged between 45 postconceptional weeks and16 years old.

Baseline SpO2 and lung ultrasound will be performed for each patient upon arrival at the operating theatre before preoxygenation with FiO2 of 1.0 SpO2 will be measured 15 min after intubation during a 5 min long "air test" trial (FiO2 0.25). lung collapse will be verified by lung ultrasound at the end of the 15 min trial. Lung collapse will be eventually granted upon lung US verification by a blind researcher.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Collapse Lung Diseases Atelectasis Atelectasis Without Respiratory Distress Syndrome Atelectases, Resorption Air Test Pediatric Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Lung Collapse will be diagnosed by a blind researcher that does not know the air test results

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Air test

Group Type EXPERIMENTAL

Air test

Intervention Type DIAGNOSTIC_TEST

Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Air test

Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* General anesthesia
* Perioperative risk classification (ASA) I, II, III
* Newborns (postconceptional age\> 45 weeks) to 16 years
* Need for oral / nasotracheal intubation

Exclusion Criteria

* ASA \> III
* Basal SpO2 \< 97% on air in supine position
* Preoperative need for oxygen therapy and / or high-flow nasal cannulas
* Expected Difficult airway
* Presence of craniofacial disorders that may compromise ventilation
* Hemodynamic instability and / or need for inotropics
* History of untreated heart disease
* Presence or history of pneumothorax
* Presence of untreated congenital pulmonary disorders
* Refusal to participate in the study
Minimum Eligible Age

5 Weeks

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitario La Princesa

UNKNOWN

Sponsor Role collaborator

Hospital Privado de Comunidad

UNKNOWN

Sponsor Role collaborator

Hospital Universitario La Paz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Patricio Gonzalez Pizarro

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Privado de Comunidad

Córdoba, , Argentina

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Universitario La Princesa

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HULaPaz

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.